UP
Company
올리패스· 244460
OLIPASS CORPORATION
Showing 13 RSS articles and DART filings mapped to this company, sorted by time.
- Market
- LISTED
- Items
- 13
Recent news & filings
UP
koKRtier 1 1분
[올리패스] [기재정정]반기보고서 (2026.06)
No RSS summary is available. Open the original link to read more.
UP
UP
UP
koKRtier 1 1분
[올리패스] 반기보고서 (2026.06)
No RSS summary is available. Open the original link to read more.
UP
koKRtier 1 1분
[올리패스] 반기검토(감사)의견부적정등사실확인(자본잠식률100분의50이상또는자기자본10억원미만포함)
No RSS summary is available. Open the original link to read more.
UP
koKRtier 1 1분
[올리패스] 기타시장안내 (상장적격성 실질심사 사유 추가 관련 절차 미진행)
No RSS summary is available. Open the original link to read more.
UP
UP
koKRtier 1 1분
[올리패스] 기타시장안내 (회생절차 개시결정 관련 시장안내)
No RSS summary is available. Open the original link to read more.
UP
koKRtier 1 1분
[올리패스] [Correction] Major Management Matters Related to Investment Decisions (Receipt of R&D Expenses for Joint New Drug R&D)ko→en
No RSS summary is available. Open the original link to read more.
UP
koKRtier 1 1분
[OliPass] [Correction] Key management matter related to investment judgment (Receipt of R&D expenses for joint new drug R&D)ko→en
No RSS summary is available. Open the original link to read more.
UP
koKRtier 1 1분
[올리패스] [Correction] Key Management Matters Related to Investment Judgment (Receipt of R&D Expenses for Joint New Drug Research and Development)ko→en
No RSS summary is available. Open the original link to read more.
UP
koKRtier 1 1분
[OliPass] [Correction] Major Management Matters Related to Investment Judgment (Joint R&D Agreement with Vanda Pharmaceuticals for Rare Disease and Immuno-Oncology Therapies Based on OliPass PNA Platform Technology)ko→en
No RSS summary is available. Open the original link to read more.